Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting
- 1 October 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 23 (10), 535-548
- https://doi.org/10.1097/fpc.0b013e3283649b9a
Abstract
Objective The objective was to evaluate the potential benefit of an integrated, five-gene pharmacogenomic test and interpretive report (GeneSight) for the management of psychotropic medications used to treat major depression in an outpatient psychiatric practice. Methods The open-label study was divided into two groups. In the first (unguided) group (n=113), pharmacogenomic information was not shared until all participants completed the study. In the second (guided) group (n=114), the pharmacogenomic report was provided to physicians for clinical use. Three depression ratings, the 17-item Hamilton Rating Scale for Depression (HAMD-17), the Quick Inventory of Depressive Symptomatology – Clinician Rated (QIDS-C16), and the Patient Health Questionnaire (PHQ-9), were collected at baseline, and at 2, 4, and 8 weeks. Results The guided group experienced greater percent improvement in depression scores from baseline on all three depression instruments (HAMD-17, PPPP=0.03; QIDS-C16, P=0.005; PHQ-9, P=0.01). Eight-week QIDS-C16 remission rates were higher in the guided group (P=0.03). Participants in the unguided group who at baseline were prescribed a medication that was most discordant with their genotype experienced the least improvement compared with other unguided participants (HAMD-17, P=0.007). Participants in the guided group and on a baseline medication most discordant with their genotype showed the greatest improvement compared with the unguided cohort participants (HAMD-17, P=0.01). Conclusion These findings replicate previous studies and demonstrate significantly improved depression outcomes with use of GeneSight, an integrated, multigenetic pharmacogenomic testing platform.Keywords
This publication has 15 references indexed in Scilit:
- Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practiceActa Psychiatrica Scandinavica, 2011
- Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trialsBMJ Open, 2011
- How change comes: translating biological research into careThe Psychiatrist, 2011
- Facilitating Clinical Implementation of PharmacogenomicsJAMA, 2011
- Reengineering Translational Science: The Time Is RightScience Translational Medicine, 2011
- Serotonin Transporter Gene Promotor Polymorphism (5-HTTLPR) Associations with Number of Psychotropic Medication Trials in a Tertiary Care Outpatient Psychiatric Consultation PracticePsychosomatics, 2011
- Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trialEuropean Psychiatry, 2006
- Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseMolecular Psychiatry, 2004
- The PHQ-9Journal of General Internal Medicine, 2001
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960